Galsulfase IV

Galsulfase IV

Form: Lyophilized powder for IV

Strength: 1mg/ml

Reference Brands: Vimizim®(US & EU)

Category: Orphan Drugs

Galsulfase, marketed as Vimizim®, is approved in the US and EU for mucopolysaccharidosis type IVA (Morquio A syndrome). Regulatory dossiers include comprehensive clinical trial data, manufacturing practices, and safety profiles submitted to FDA and EMA, supporting its approval. Dossiers demonstrate its efficacy in reducing symptoms and improving mobility. Administered via IV infusion, dosing is individualized according to patient weight. For in-depth insights on regulatory submissions, dossier requirements, and market approvals, visit PharmaTradz, your trusted source for pharmaceutical regulatory updates and industry insights.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Alglucosidase Alfa IV

Strength: 50 mg/vial

Form: Lyophilized powder

Reference Brands: Lumizyme®(US & EU)

View Details Get Enquiry
Nitisinone tablets

Strength: 2 mg and 5 mg

Form: Tablets

Reference Brands: Orfadin®

View Details Get Enquiry
Treprostinil IV or SC

Strength: 2 mg (0.1 mg/mL), 4 mg (0.2 mg/mL), 8 mg (0.4 mg/mL), 20 mg (1 mg/mL), 50 mg (2.5 mg/mL), 100 mg (5 mg/mL), 200 mg (10 mg/mL), or 400 mg (20 mg/mL)

Form: SC or Intravenous (IV)

Reference Brands: Remodulin®(US & EU)

View Details Get Enquiry
Iloprost inahalation Solution

Strength: 10 mcg/mL

Form: Inhalation Solution (Nebulizer)

Reference Brands: Ventavis®(EU & US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.